TABLE 1.
Characteristics of the 15 compounds showing antitoxoplasmic activity after preliminary screening at 1 μM
| Anti-Toxoplasma gondii compounda | Mol wtb | cLogPb | Targetb |
|---|---|---|---|
| MMV676477 | 383.47 | 3.28 | Tuberculosis |
| MMV676512 | 347.39 | 2.95 | Tuberculosis |
| MMV676604 | 371.46 | 2.11 | Kinetoplastids |
| MMV688853 | 389.88 | 1.75 | Cryptosporidiosis |
| MMV689480 | 326.43 | 4.69 | Leishmaniasis |
| MMV676602 | 460.57 | 2.09 | Kinetoplastids |
| MMV687807 | 383.67 | 2.63 | Tuberculosis |
| MMV011765 | 358.73 | 3.10 | Malaria |
| MMV022478 | 545.93 | 2.55 | Malaria |
| MMV675968 | 359.81 | 2.31 | Cryptosporidiosis |
| MMV659004 | 364.88 | 4.39 | Kinetoplastids |
| MMV658988 | 338.84 | 3.93 | Kinetoplastids |
| MMV676599 | 331.41 | 3.36 | Cryptosporidiosis |
| MMV021013 | 294.40 | 3.55 | Tuberculosis |
| MMV688703 | 335.42 | 4.03 | Toxoplasmosis |
a
Compounds are named by their MMV identifier codes.
b
Molecular weight (Mol wt), cLogP values, and initial activities of the compounds were obtained from the Pathogen Box supporting information.